Anti-Cancer Antibodies

Anticancer antibodies  has created great interest in antibody-based therapeutics for hematopoietic malignant neoplasms and solid tumors. Given the likelihood of lower toxic effects of antibodies that target tumor cells and have limited impact on nonmalignant bystander organs vs small molecules, the potential increased efficacy by conjugation to radioisotopes and other cellular toxins, and the ability to characterize the target with clinical laboratory diagnostics to improve the drug's clinical performance, current and future antibody therapeutics are likely to find substantial roles alone and in combination therapeutic strategies for treating patients with cancer. Therapeutic antibodies have become a major strategy in clinical oncology owing to their ability to bind specifically to primary and metastatic cancer cells with high affinity and create antitumor effects by complement-mediated cytolysis and antibody-dependent, cell-mediated cytotoxicity (naked antibodies) or by the focused delivery of radiation or cellular toxins (conjugated antibodies).

Novel antibody-based structures with multiple antigen-recognition sites, altered size or effector domains have been shown to influence the targeting ability of antibodies. This review will focus on novel approaches of antibody-based cancer therapy.

  • Antibodies in Treatment of Cancer
  • Characterizing and clinical use of Circulating Tumor Cells (CTCS)
  • Advances in tumor modeling, cancer drug discovery and development
  • Translational approaches in cancer immunotherapy development
  • Innovative in vitro and in vivo modeling

Related Conference of Anti-Cancer Antibodies

Anti-Cancer Antibodies Conference Speakers